Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]
ALTTO 试验的最终分析：曲妥珠单抗序贯或联合拉帕替尼治疗 HER2 阳性早期乳腺癌患者 [BIG 2-06/NCCTG N063D (Alliance)]
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.103938
de Azambuja, E; Piccart-Gebhart, M; Fielding, S; Townend, J; Hillman, D W; Colleoni, M; Roylance, R; Kelly, C M; Lombard, J; El-Abed, S; Choudhury, A; Korde, L; Vicente, M; Chumsri, S; Rodeheffer, R; Ellard, S L; Wolff, A C; Holtschmidt, J; Lang, I; Untch, M; Boyle, F; Xu, B; Werutsky, G; Tujakowski, J; Huang, C-S; Baruch, N B; Bliss, J; Ferro, A; Gralow, J; Kim, S-B; Kroep, J R; Krop, I; Kuemmel, S; McConnell, R; Moscetti, L; Knop, A S; van Duijnhoven, F; Gomez, H; Cameron, D; Di Cosimo, S; Gelber, R D; Moreno-Aspitia, A
